Myxopyronin Derivatives Inhibit Bacterial RNA Polymerase Switch Region
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing prevalence of rifamycin-resistant and multidrug-resistant bacterial infections poses a significant public health threat, as existing antibacterial agents like rifamycins are becoming less effective due to resistance, necessitating new compounds that inhibit bacterial RNA polymerase without overlapping the rifamycin binding site to avoid cross-resistance.
Innovation Solution
Development of compounds that target the switch region of bacterial RNA polymerase, such as myxopyronin analogues, which bind to a non-overlapping site, inhibiting bacterial gene expression and killing bacteria without conferring cross-resistance with rifamycins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rifamycins are used to treat bacterial infections, then antibacterial activity is achieved, but bacterial resistance develops reducing treatment effectiveness
Solution Approach 1:
The invention divides the antibacterial strategy into two distinct segments: rifamycins targeting the rifamycin binding site on RNAP, and myxopyronin derivatives targeting the switch region. This segmentation allows each agent to act through a different mechanism and binding site, preventing cross-resistance and maintaining reliable antibacterial activity even when resistance to one agent develops
Solution Approach 2:
The myxopyronin derivative acts as an intermediary agent that binds to the switch region of bacterial RNAP, a site distinct from the rifamycin binding site. This intermediary binding mechanism inhibits RNAP activity through a different pathway, providing an alternative route for antibacterial action that bypasses rifamycin resistance mechanisms
2Adaptability or versatility
If new antibacterial agents targeting the switch region are developed, then cross-resistance with rifamycins is avoided, but compound complexity increases
Solution Approach 1:
The invention applies local quality by modifying specific regions of the myxopyronin molecule (particularly the R1 and R2 substituents on the pyrone ring) to optimize binding to the switch region. These localized structural modifications enhance cross-resistance avoidance while maintaining reasonable molecular complexity through targeted rather than comprehensive structural changes
Solution Approach 2:
The invention employs parameter changes by systematically varying substituent groups (R1, R2, R3, R4, R5, R6) at different positions on the myxopyronin core structure. This allows optimization of binding affinity and selectivity for the switch region while controlling molecular complexity through deliberate parameter adjustment rather than fundamental structural redesign
Data Source
AI summary
The invention provides compounds of formula la, lb and Ic: [Formula Ia, Ib, and Ic] and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula Ia-Ic, methods of making such compounds, and methods of using such compounds, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.